NYSE$ELAN

Elanco Animal Health Inc · Q1 2025 earnings

Q1 2025 earnings · · Before market open · Investor relations

Briefing

Elanco Animal Health reported Q1 2025, revenue of $1.19B, net income of $67M, diluted EPS of $0.13.

For Q1 2025, Elanco Animal Health reported revenue of $1.19B, net income of $67M, diluted EPS was $0.13. Management discusses operating trends, capital, and sector risks in the quarterly filing.

  • Q1 2025 revenue $1.19B.
  • Net income $67M.
  • Diluted EPS $0.13.

Headline financials

Total Revenue

$1.19B

Previous: $1.21B-1.0%
EPS (adj)

$0.13

Previous: $0.06+116.7%
Organic CC Revenue Growth

4.0%

No prior period
Adjusted EBITDA

$276M

Previous: $294M-6.1%
Adjusted EBITDA Margin

23.1%

Previous: 24.4%-5.3%
Gross Profit Margin

57.3%

No prior period
Net Leverage Ratio

4.4

No prior period
Capital Expenditures

-$65M

Previous: -$24M-170.8%
Net Income

$67M

Previous: $32M+109.4%
Operating Income

$60M

Previous: -$1.12B+105.4%
Gross Profit

$684M

Previous: $690M-0.9%

Revenue & EPS history

Elanco · Revenue · Quarterly

$1.19B

Q1 2025-1%vs Q1 2024
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Elanco · $1.58B total across 5 segments · Q3 2023

  • Farm Animal
    $561M
  • Pet Health
    $495M+5.1%
  • Cattle
    $242M+3.9%
  • Poultry
    $184M+15.7%
  • Swine
    $93M+10.7%

Forward guidance

Consumer and animal-health operators focus on brand momentum, category growth, and cost programs.

Tailwinds

  • Brand reinvestment and digital engagement.
  • New product launches and market share gains.
  • Productivity and restructuring savings.

Headwinds

  • Promotional environment and inventory clearance.
  • China and tourism-dependent demand swings.
  • Input cost inflation on packaging and logistics.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+2.0%

Avg return

Earnings day

+2.8%

Avg return

5 days after

+1.1%

Avg return

30 days after

52%

16 / 31 earnings

Positive

+27.2%

Q1 2024

Best reaction

-16.3%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+13.9%-5.6%+2.6%
Q4 2025+7.3%+6.7%-0.7%
Q3 2025-4.2%-1.0%-2.7%
Q1 2025+26.2%+34.8%+46.2%
Q4 2024-3.7%+0.5%-2.7%
Q3 2024+9.4%+9.8%-2.8%
Q2 2024+5.3%+12.6%+21.9%
Q1 2024+27.2%+25.7%+34.7%
Q4 2023+0.5%-2.1%-1.2%
Q3 2023+15.9%+14.1%+36.4%
Q2 2023+7.0%+4.5%+2.7%
Q1 2023-3.8%-8.4%-0.1%
Q4 2022-6.9%-11.0%-33.1%
Q3 2022-10.3%+0.4%-6.7%
Q2 2022-1.6%+3.3%-23.9%
Q1 2022-7.9%-6.4%+1.5%
Q4 2021+8.2%+12.4%+3.3%
Q3 2021+1.2%+0.3%-14.3%
Q2 2021-16.3%-12.3%-4.2%
Q1 2021+3.8%+3.4%+10.1%
Q4 2020+2.8%+9.0%-9.8%
Q3 2020-4.7%-8.0%-9.8%
Q2 2020+11.7%+17.3%+37.7%
Q1 2020-13.5%-12.9%+3.6%
Q4 2019-0.7%-1.4%-42.5%
Q3 2019-1.9%-3.1%-1.2%
Q2 2018-4.8%-1.3%-4.6%
Q2 2019-4.8%-1.3%-4.6%
Q1 2019+6.1%+3.9%+4.1%
Q4 2018-2.4%-1.7%-2.7%
Q3 2018+3.7%+3.7%-1.9%
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro